Modern Vaccine and Biologics Manufacturing Strategy
Transcript of Modern Vaccine and Biologics Manufacturing Strategy
![Page 1: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/1.jpg)
Prepared for AndyJuly 08, 2021
Modern Vaccine and Biologics Manufacturing Strategy
![Page 2: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/2.jpg)
Cytiva 2
Precision medicine for cancer
![Page 3: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/3.jpg)
Cytiva 3
新冠病毒疫苗,主要關注抗原依然是 S抗原
February 19,2020
減毒病毒疫苗
滅活病毒疫苗
減毒細菌疫苗
滅活細菌疫苗
蛋白疫苗
多糖疫苗
多糖蛋白結合疫苗
病毒樣顆粒(VLP)
病毒載體疫苗
DNA疫苗
mRNA疫苗
Covid-19 vaccine development
![Page 4: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/4.jpg)
Cytiva 4
Immune cellsare
collected by a
procedure called
apheresis
107 T cells
50-100mL
Cells are tested for safety and
potency and packaged for
injection back into thepatient
Cells are
reinfused
into the
patient at
clinical
center
108 T cells
50-100mL
107 T cells
50-100mL
Biopharma, Cell therapy and Vaccine
![Page 5: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/5.jpg)
Cytiva工藝開發流程
工藝放大流程
Biopharma, Cell therapy and Vaccine tall tale Solution
![Page 6: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/6.jpg)
Introduction to protein purification
![Page 7: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/7.jpg)
7
Sample purification and preparation
![Page 8: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/8.jpg)
TherapeuticsDiagnostics
Functional Studies
Structural Studies
Basic Research
PurifiedProtein
TherapeuticsAntibodyVaccine
AntibioticHormoneCytokinesEnzyme
InhibitorsTest reagentsBiomaterial
Sample purification
![Page 9: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/9.jpg)
UV
Column Gel media
Crude sample Buffer
Monitors
Collection
9
Chromatography
![Page 10: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/10.jpg)
Chromatography principle
29160894AA | June 2015 10
Medium
Sample
Target protein
Buffer
Other molecules
![Page 11: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/11.jpg)
Protein properties that matter for protein purification
Hydrophobicity
Net charge
Size
Ion exchange chromatography (IEX)
Affinity chromatography (AC)
Hydrophobic interaction chromatography (HIC)
Size exclusion chromatography (SEC)or gel filtration
Biospecific affinity(e.g., a tag)
11
![Page 12: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/12.jpg)
The principles of chromatography techniques
12
Affinity Chromatography(AC)
Ion exchange Chromatography(IEX)
Hydrophobic interaction Chromatography(HIC)
Size exclusionChromatography(SEC)
• Bind – elute principle
• Requires specific elution conditions
• Concentrating effect
• Diffusion – no binding
• Any elution conditions
• Diluting effect
![Page 13: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/13.jpg)
Purification strategy
![Page 14: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/14.jpg)
Purification protocol development - step by step
Define the purification objectives
Consider what’s
known about the target
protein
Develop the individual
purification steps
Combine techniques
Develop analytical
assays
![Page 15: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/15.jpg)
Introduction to CiPP purification strategy
Purity
15
Stage
Sample prep
Capture
Isolate, concentrate and stabilize
intermediate
Purification
Remove bulk impurities
PolishingRemove finalcontaminants
Yield (%)
Number of purification steps
Protein recovery plotted against the number of purification steps
Purification strategy combining multiple steps
![Page 16: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/16.jpg)
How to combine purification techniques
AC
SEC
AC
IEX
AC
HIC IEX
IEX
SEC SEC
HIC
Use orthogonal techniques and minimize sample handling
IEX
Capture
Intermediate purification
Polishing
16
![Page 17: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/17.jpg)
17
ÄKTA™ system provides efficient purification of your target protein
![Page 18: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/18.jpg)
Cytiva 18Ref.: https://m.match.net.tw/pc/life/health/20210612/5921991
![Page 19: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/19.jpg)
Cytiva 19
Ref.: https://www.nature.com/articles/s41563-020-0746-0
Different types of vaccine
![Page 20: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/20.jpg)
Cytiva
1Sub-unit vaccine
• Additional content, if needed
20
![Page 21: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/21.jpg)
Cytiva 21
Recombinant protein
Plasmid Construction
Protein expression
clarification and
filtration
Protein purification
Functional Analysis
To produce large quantities of the protein of interest
cDNA
Plasmid
2HN
COOH
2HN
COOH
![Page 22: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/22.jpg)
Cytiva 22
There are many ways to improve protein purity and yield
• Sample conditions
• Optimize binding conditions
• Optimize elution conditions
• Multi-step purificationNo imidazole in the binding buffer Imidazole in the binding buffer
![Page 23: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/23.jpg)
Cytiva 23
Impact of multi-step purification on protein purity
97 000
66 000
45 000
30 000
20 100
14 400
Mr
97 000
66 000
45 000
30 000
20 100
14 400
Mr
97 000
66 000
45 000
30 000
20 100
14 400
Mr
1 3 4 5 6 7 8 92
LMW Start FT wash eluted 1 2 3
HisTrap Superdex
F
Desalting
AffinityGST His Ab
Gel filtration
Size exclution
![Page 24: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/24.jpg)
Cytiva 24Viral fusion core
The function of Spike glycolprotein
![Page 25: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/25.jpg)
Cytiva 25
Vaccine based on S protein
• Full-length S protein
• RBD/FC fusion protein
![Page 26: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/26.jpg)
Cytiva 26
Different Tag technologies
Fc domain-ProteinA Nickel-Histidine
![Page 27: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/27.jpg)
Cytiva
Fc fusion protein Purification Toolboxes
Two-step process
Capto S ImpAct
Capto Q /
ReadyToProcess™
Adsorber Q
Three-step process
MabSelect™ PrismA MabSelect PrismA
Capto™ adhere (FT)
Capto adhere ImpRes (FT)
Capto MMC
Capto adhere (FT)
Capto adhere ImpRes (FT)
Capto adhere ImpRes (B/E)
Three-step process
MabSelect PrismA
B/E = bind and elute, FT = flow-through
27
![Page 28: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/28.jpg)
Cytiva 28
His-Tagged protein Purification Toolboxes
Main characteristics:
1. High binding capacity: ~ 40 mg/mL
2. High flow rate: 150 ~200 cm/hr
3. BioProcess resin: Regulatory suppot file (RSF)
4. RSF containing: Product Quality, Product stability, Excretable compound, Manufacturing description..etc.
Ni Sepharose 6 Fast Flow
IMAC Sepharose 6 Fast Flow
![Page 29: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/29.jpg)
Cytiva 29
Process workflow
Upstream Production
Clarification
Concentration and Buffer exchange
Capture: MabselectPrismA
Polishing: Capto adhere
Capture: IMAC 6 FF
Polishing1: Capto MMC
Polishing 2: Capto Q
Virus Filtration
Formulation
Sterile Filtration
Case Sharing
• RBD/FC fusion protein • Full-length S protein
![Page 30: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/30.jpg)
Cytiva
2Virus vector vaccine
30
![Page 31: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/31.jpg)
Cytiva
The sizes of viral vectors
Adenovirus (AdV)
~ 90 nm
Lentivirus
~ 80–120 nm
Adeno-associated
virus (AAV)
~ 25 nm
Antibody
~ 5 nm
31
![Page 32: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/32.jpg)
Cytiva
Recombinant virus vectors for cell- and gene therapy
Preventive vaccines
Rota (80 nm)
Polio (30 nm)
HAV (30 nm)
Hep B
AAV (25 nm) Adeno
(70–90 nm)
Flu (90–120
nm) Rabies (75 × 180 nm)
Mumps (200 nm)
Measles (100 × 300 nm)
Pox (200 × 300 nm)
Lenti (80–120)
JE
Yellow Fever
VLP
(40–60 nm)
(40–60 nm)
(40–60 nm)
(42 nm)
11/30/202132
Sizes of common viruses
![Page 33: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/33.jpg)
Cytiva 33
Adenovirus vector platform
![Page 34: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/34.jpg)
Cytiva 34
5 µm inactive shell
85 µm particle size
N+
Octylamine - Multimodal ligandVery strong protein binding
Viral particle
Host cell proteins (HCP)DNA fragmentsEndotoxinsDetergentsBenzonase™Etc…
Concept
Capto™ Core 700
![Page 35: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/35.jpg)
Cytiva
Features and benefits
High purity and yield with high load
Purity and yield
Capto™ Core 700 achieves the same HCP removal and virus recovery as gel filtration
Load and dilution
Capto Core 700 allows this purity and yield to be obtained with significantly higher load and without any dilution to the feed
High productivity without compromising purity or yield!
![Page 36: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/36.jpg)
Cytiva 36
Benefits of Capto Core
• Saving Column volume • More sample volume
![Page 37: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/37.jpg)
Cytiva 37
Adenovirus vector platform
![Page 38: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/38.jpg)
Cytiva 38
![Page 39: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/39.jpg)
Cytiva 39
Adenovirus vector platform
![Page 40: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/40.jpg)
Cytiva
3mRNA vaccine• Additional content, if needed
40
![Page 41: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/41.jpg)
Cytiva 41
Ref.: https://theconversation.com/what-is-mrna-the-messenger-molecule-thats-been-in-every-living-cell-for-billions-of-years-is-the-key-ingredient-in-some-covid-19-vaccines-158511
How mRNA vaccine works?
![Page 42: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/42.jpg)
Cytiva 42
Transcription with RNA polymerase (IVT, In-vitro transcription)
mRNA purificationGet plasmid DNA Encapsulated mRNA
Strategy for producing mRNA vaccine
![Page 43: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/43.jpg)
Cytiva
Plasmid and mRNA manufacturing process
Cell expansion and production
Cell concentration
Lysis Clarification ConcentrationGroup
separationCapture Polishing
Formulation and sterile filtration
Bulk fill
Synthesis from
pDNA template
Optional conditioning
mRNA capture
Formulation Bulk fillEncapsulation
and LNP formation
Polishing purification OR
filtration
Formulation and fill
CappingOptional
condition
1. Plasmid manufacturing
3. mRNA encapsulation2. mRNA manufacturing
LNP, lipid nanoparticle.
![Page 44: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/44.jpg)
Cytiva 44
![Page 45: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/45.jpg)
Cytiva 45
![Page 46: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/46.jpg)
Cytiva
Plasmid and mRNA manufacturing process
Cell expansion and production
Cell concentration
Lysis Clarification ConcentrationGroup
separationCapture Polishing
Formulation and sterile filtration
Bulk fill
Synthesis from
pDNA template
Optional conditioning
mRNA capture
Formulation Bulk fillEncapsulation
and LNP formation
Polishing purification OR
filtration
Formulation and fill
CappingOptional
condition
1. Plasmid manufacturing
3. mRNA encapsulation2. mRNA manufacturing
LNP, lipid nanoparticle.
![Page 47: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/47.jpg)
Cytiva
mRNA manufacturing & purification
47
IVTUF/DF
Desalting
Oligo dT, Affinity
Polishing/Conc.Capto Core 700/
Hollow FiberCapping Sterile Filtration
Synthesis from
pDNA template
mRNA capture
dsRNA remove
Sterile filtration
Capping
Fibro Oligo dT
Sera-Mag Oligo(dT)-Coated
Source 15Q
HiRes QCapto core 400
dsRNA remove
![Page 48: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/48.jpg)
Cytiva 48
Adenovirusvector
Upstream Productio
n
Cell Lysis and DNA
fragmentation
Clarification
UF/DFCapto Q ImpRes
CaptoCore 700 Formulation
Sterile Filtration
Spike proteinUpstream
ProductionClarification UF/DF
His-tagged, Affinity
CaptoMMC
Capto Q
MabSelect PrismACapto
Adhere
FormulationVirus
FiltrationSterile
Filtration
Plasmid DNA Fermentation Harvest Lysis Clarification UF/DFSepharose
6 FF
CaptoPlasmidSelect
Capto Q ImpRes
Formulation
mRNA IVT UF/DFOligo dT, Affinity
Polishing/Conc.
EncapsulationCapto Core 700/
Hollow FiberFormulation
Sterile Filtration
Summarized the Modern Vaccines
Adenovirusvector
Upstream Production
Cell Lysis and DNA
fragmentationClarification UF/DF
Capto Q ImpRes
CaptoCore 700
FormulationSterile
Filtration
Spike protein Upstream Production
Clarification UF/DF
His-tagged, Affinity
CaptoMMC
Capto Q
MabSelect PrismACapto
Adhere
FormulationVirus
FiltrationSterile
Filtration
![Page 49: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/49.jpg)
Cytiva
Ä KTA System
49
![Page 50: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/50.jpg)
Cytiva 50
Proven technologyContinues ÄKTA™ tradition
• Incorporates over 50 years of experience in protein research
• Backed by 30 years of experience in developing protein purification systems
• ÄKTA systems are used by 100,000 researchers globally
•2012—ÄKTA pure: protein purification your way
1982—FPLC™ system released, predecessor to ÄKTA systems
1996—ÄKTAexplorer™,
single platform for all chromatography techniques1959—Sephadex™, the world’s
first gel filtration medium
2015 upgrade
2019—ÄKTA™ go : provides efficient purification of your target protein
![Page 51: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/51.jpg)
Cytiva 51
Ä KTA System
ÄKTA™ pure
Functions & Price & Scale-up
ÄKTA™ avant
Flexibility in researchMatch most current and future purification challenges
Productivity in process development Fast and secure development of purification processes
ÄKTA pilot 600
Prepare for GMP environment. Smaller GMP batches for early clinical studies Scale-up and robustness testing
ÄKTA process
ÄKTAprocess is a versatile platform providing thousands of configuration possibilities. The system is available in three flow rate ranges that extend up to 2000 L/h.
AxiChrom
BPG
Hitrap
HiScreen
XK/Hiscale
![Page 52: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/52.jpg)
Cytiva 52
System pump P9 A/P9 B
ÄKTA pure25:
Flow rate: 0.001-25 ml/min
Max. flow rate: 50ml/min
Pressure: 0-20MPa
Rinsing outlet
Solution inlet
Solution outlet
Pump head rinsing system
Function:--Rinse piston;--Rinse out buffer salt;
Maintenance:20% EtOH
(change rinsing solution every two week)Rinsing inlet
![Page 53: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/53.jpg)
Cytiva 53
Air in Pump
Buffer inlet
Buffer outlet
• If air gets stuck in the pump, manual purge might be necessary
• For lower amount of air, use pump wash
Air bubble
![Page 54: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/54.jpg)
Cytiva 54
Ports and flow paths of the Injection valve
![Page 55: Modern Vaccine and Biologics Manufacturing Strategy](https://reader033.fdocuments.us/reader033/viewer/2022051323/627c260ec11b1a3cb33da303/html5/thumbnails/55.jpg)
Cytiva 55
Tailor ÄKTA™ pure to fit your needs… to full automation...